Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea

NCT02183025 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

337

Enrollment

INDUSTRY

Sponsor class

Conditions

Dysmenorrhea

Interventions

DRUG: Meloxicam 7.5 mg
DRUG: Meloxicam 15 mg
DRUG: Mefenamic acid 500 mg
DRUG: Placebo matching 7.5 mg meloxicam
DRUG: Placebo matching 15 mg meloxicam
DRUG: Placebo matching 500 mg mefenamic acid

Sponsor

Boehringer Ingelheim